Peter Rahmer - 27 Jan 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Corporate Development Officer
Signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
27 Jan 2026
Net transactions value
-$97,501
Form type
4
Filing time
29 Jan 2026, 16:22:30 UTC
Previous filing
15 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rahmer Peter Chief Corporate Development Officer C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE /s/ Soo-Yeun Lim, as Attorney-in-Fact 29 Jan 2026 0001959229

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $2,972 +994 +0.29% $2.99 338,463 31 Dec 2025 Direct F1, F2, F3
transaction RLAY Common Stock Sale $89,032 -11,684 -4% $7.62 277,964 27 Jan 2026 Direct F4, F5
transaction RLAY Common Stock Sale $11,441 -1,354 -0.49% $8.45 276,610 28 Jan 2026 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.
F3 Includes 108,919 shares underlying restricted stock units ("RSUs").
F4 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,394 shares of RSUs on January 26, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F5 Includes 17,710 shares underlying RSUs.
F6 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of RSUs on January 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F7 Includes 12,204 shares underlying RSUs.

Remarks:

Chief Corporate Development Officer